ma5 reactivity with greater than 95 % of primary and metastatic breast tumors , surface expression of the antigen , as well as its ability to localize within breast tumor xenografts prompted this initial study to determine the efficacy of ma5 to localize breast tumors by radioimmunoscanning .
C0006141
breast
C1458155
breast tumors